ProfileGDS5678 / 1452266_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 81% 81% 79% 80% 83% 76% 81% 83% 82% 80% 81% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0980883
GSM967853U87-EV human glioblastoma xenograft - Control 25.8555381
GSM967854U87-EV human glioblastoma xenograft - Control 35.862281
GSM967855U87-EV human glioblastoma xenograft - Control 45.7268479
GSM967856U87-EV human glioblastoma xenograft - Control 55.7516880
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.873783
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9596576
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8288681
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0544583
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0033882
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6146580
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9115681
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9453782
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8455682